Institution
McMaster University
Education•Hamilton, Ontario, Canada•
About: McMaster University is a education organization based out in Hamilton, Ontario, Canada. It is known for research contribution in the topics: Population & Health care. The organization has 41361 authors who have published 101269 publications receiving 4251422 citations.
Papers published on a yearly basis
Papers
More filters
••
McGill University Health Centre1, University of Ottawa2, St. Paul's Hospital3, Libin Cardiovascular Institute of Alberta4, Centre Hospitalier Universitaire de Sherbrooke5, McMaster University6, Robarts Research Institute7, University of Calgary8, University of Toronto9, Population Health Research Institute10, University of British Columbia11, University of Alberta12, McGill University13
TL;DR: The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult.
786 citations
••
TL;DR: There is synergism for the development of peptic ulcer and ulcer bleeding between H pylori infection and NSAID use and significantly increase the risk ofpeptic ulcers and ulcers bleeding.
785 citations
••
TL;DR: It is concluded that the feeding-induced simulation of MPS in young men is greater after whey hydrolysate or soy protein consumption than casein both at rest and after resistance exercise; moreover, despite both being fast proteins, whey Hydrolysate stimulated MPS to a greater degree than soy after resistance Exercise.
Abstract: This study was designed to compare the acute response of mixed muscle protein synthesis (MPS) to rapidly (i.e., whey hydrolysate and soy) and slowly (i.e., micellar casein) digested proteins both a...
784 citations
••
TL;DR: Data are compatible with the hypothesis that AIF is a caspase‐independent mitochondrial death effector responsible for partial chromatinolysis, and in conditions of ATP depletion, AIF translocation correlates with the appearance of large‐scale DNA fragmentation.
Abstract: Apoptosis inducing factor (AIF) is a novel apoptotic effector protein that induces chromatin condensation and large-scale (∼50 kbp) DNA fragmentation when added to purified nuclei in vitro. Confocal and electron microscopy reveal that, in normal cells, AIF is strictly confined to mitochondria and thus colocalizes with heat shock protein 60 (hsp60). On induction of apoptosis by staurosporin, c-Myc, etoposide, or ceramide, AIF (but not hsp60) translocates to the nucleus. This suggests that only the outer mitochondrial membrane (which retains AIF in the intermembrane space) but not the inner membrane (which retains hsp60 in the matrix) becomes protein permeable. The mitochondrio-nuclear redistribution of AIF is prevented by a Bcl-2 protein specifically targeted to mitochondrial membranes. The pan-caspase inhibitor Z-VAD.fmk does not prevent the staurosporin-induced translocation of AIF, although it does inhibit oligonucleosomal DNA fragmentation and arrests chromatin condensation at an early stage. ATP deple...
784 citations
••
Memorial Sloan Kettering Cancer Center1, University of California, Los Angeles2, Yale University3, Fox Chase Cancer Center4, Johns Hopkins University5, Duke University6, University of Texas Southwestern Medical Center7, University of Washington8, McMaster University9, Princess Margaret Cancer Centre10, University of Ottawa11, Bristol-Myers Squibb12
TL;DR: The primary outcome was safety and tolerability, assessed in all treated patients, and data from the latter two cohorts, which were considered potentially suitable for further clinical development, are presented.
Abstract: Summary Background Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC. Methods The open-label, phase 1, multicohort study (CheckMate 012) cohorts reported here were enrolled at eight US academic centres. Eligible patients were aged 18 years or older with histologically or cytologically confirmed recurrent stage IIIb or stage IV, chemotherapy-naive NSCLC. Patients were randomly assigned (1:1:1) by an interactive voice response system to receive nivolumab 1 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks, nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 12 weeks, or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks until disease progression, unacceptable toxicities, or withdrawal of consent. Data from the latter two cohorts, which were considered potentially suitable for further clinical development, are presented in this report; data from the other cohort (as well as several earlier cohorts) are described in the appendix. The primary outcome was safety and tolerability, assessed in all treated patients. This ongoing study is registered with ClinicalTrials.gov, number NCT01454102. Findings Between May 15, 2014, and March 25, 2015, 78 patients were randomly assigned to receive nivolumab every 2 weeks plus ipilimumab every 12 weeks (n=38) or nivolumab every 2 weeks plus ipilimumab every 6 weeks (n=40). One patient in the ipilimumab every-6-weeks cohort was excluded before treatment; therefore 77 patients actually received treatment (38 in the ipilimumab every-12-weeks cohort; 39 in the ipilimumab every-6-weeks cohort). At data cut-off on Jan 7, 2016, 29 (76%) patients in the ipilimumab every-12-weeks cohort and 32 (82%) in the ipilimumab every-6-weeks cohort had discontinued treatment. Grade 3–4 treatment-related adverse events occurred in 14 (37%) patients in the ipilimumab every-12-weeks cohort and 13 (33%) patients in the every-6-weeks cohort; the most commonly reported grade 3 or 4 treatment-related adverse events were increased lipase (three [8%] and no patients), pneumonitis (two [5%] and one [3%] patients), adrenal insufficiency (one [3%] and two [5%] patients), and colitis (one [3%] and two [5%] patients). Treatment-related serious adverse events were reported in 12 (32%) patients in the ipilimumab every-12-weeks cohort and 11 (28%) patients in the every-6-weeks cohort. Treatment-related adverse events (any grade) prompted treatment discontinuation in four (11%) patients in the every-12-weeks cohort and five (13%) patients in the every-6-weeks cohort. No treatment-related deaths occurred. Confirmed objective responses were achieved in 18 (47% [95% CI 31–64]) patients in the ipilimumab every-12-weeks cohort and 15 (38% [95% CI 23–55]) patients in the ipilimumab every-6-weeks cohort; median duration of response was not reached in either cohort, with median follow-up times of 12·8 months (IQR 9·3–15·5) in the ipilimumab every-12-weeks cohort and 11·8 months (6·7–15·9) in the ipilimumab every-6-weeks cohort. In patients with PD-L1 of 1% or greater, confirmed objective responses were achieved in 12 (57%) of 21 patients in the ipilimumab every-12-weeks cohort and 13 (57%) of 23 patients in the ipilimumab every-6-weeks cohort. Interpretation In NSCLC, first-line nivolumab plus ipilimumab had a tolerable safety profile and showed encouraging clinical activity characterised by a high response rate and durable response. To our knowledge, the results of this study are the first suggestion of improved benefit compared with anti-PD-1 monotherapy in patients with NSCLC, supporting further assessment of this combination in a phase 3 study. Funding Bristol-Myers Squibb.
784 citations
Authors
Showing all 41721 results
Name | H-index | Papers | Citations |
---|---|---|---|
Salim Yusuf | 231 | 1439 | 252912 |
Gordon H. Guyatt | 231 | 1620 | 228631 |
Simon D. M. White | 189 | 795 | 231645 |
George Efstathiou | 187 | 637 | 156228 |
Stuart H. Orkin | 186 | 715 | 112182 |
Terrie E. Moffitt | 182 | 594 | 150609 |
John J.V. McMurray | 178 | 1389 | 184502 |
Jasvinder A. Singh | 176 | 2382 | 223370 |
Deborah J. Cook | 173 | 907 | 148928 |
Andrew P. McMahon | 162 | 415 | 90650 |
Jack Hirsh | 146 | 734 | 86332 |
Holger J. Schünemann | 141 | 810 | 113169 |
John A. Peacock | 140 | 565 | 125416 |
David Price | 138 | 1687 | 93535 |
Graeme J. Hankey | 137 | 844 | 143373 |